Clinical Trial Update: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) [Phase 1, Phase 2]

View source ↗

Summary

The GOING trial assessed regorafenib followed by nivolumab in hepatocellular carcinoma across Phase 1 and Phase 2, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Stivarga (regorafenib)

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED